SCHEMBL4501744

SCHEMBL4501744

Cc1ccc(C(=O)Nc2nnc(C(=O)Nc3ccc(N4CCOCC4)cc3)o2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.81
NPC1 O15118 3/20 0.74
RAB9A P51151 3/20 0.74
TP53 P04637 1/20 0.74
PKM P14618 1/20 0.74
MAPK1 P28482 1/20 0.74
MAPT P10636 8/20 0.61
ATM Q13315 1/20 0.61
LMNA P02545 3/20 0.60
ALDH1A1 P00352 3/20 0.60
KDM4E B2RXH2 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
MCL1 Q07820 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
CYP2C19 P33261 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4514262 0.90 DGAT1 (0.78) DGAT1NPC1RAB9ATP53PKM
SCHEMBL4494171 0.89 DGAT1 (0.81) DGAT1NPC1RAB9ATP53PKM
SCHEMBL13755344 0.89 DGAT1 (1.00) DGAT1NPC1RAB9ATP53PKM
SCHEMBL3539113 0.89 DGAT1 (0.82) DGAT1NPC1RAB9ATP53PKM
SCHEMBL4506702 0.89 DGAT1 (1.00) DGAT1NPC1RAB9ATP53PKM
SCHEMBL4518459 0.89 MAPT (0.74) DGAT1NPC1RAB9ATP53PKM
SCHEMBL4517196 0.88 DGAT1 (0.78) DGAT1NPC1RAB9ATP53PKM
SCHEMBL4493559 0.87 DGAT1 (0.76) DGAT1NPC1RAB9ATP53PKM
SCHEMBL13907635 0.86 NPC1 (1.00) NPC1RAB9ATP53PKMMAPK1
SCHEMBL4517204 0.86 MAPT (0.77) DGAT1NPC1RAB9ATP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US claimed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP claimed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO claimed
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2009-08-27 US disclosed
EP-1893592-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS AstraZeneca AB (SE) 2008-03-05 EP disclosed
WO-2006134317-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215779-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT2, GPR119, DGAT1 DGAT1 3/4885NPC1 655/4885RAB9A 1984/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.